Age-dependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea.


Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
07 2019
Historique:
received: 01 08 2018
revised: 26 11 2018
accepted: 16 12 2018
pubmed: 19 1 2019
medline: 30 4 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

In obstructive sleep apnoea (OSA), intermittent hypoxia (IH) compromises immune surveillance through the upregulation of the programmed cell death-1 (PD-1) receptor and its ligand (PD-L1). Because the risk of OSA-related cancer depends on age, we assessed PD-L1/PD-1 expression in middle-aged and older patients with OSA as well as in a murine model. PD-L1 expression was studied in 41 patients with severe OSA and 40 healthy volunteers (HV), divided into two groups (≤55 and >55 years of age). We used flow cytometry, quantitative PCR (qPCR) and ELISA to determine PD-L1 expression on monocytes and plasma PD-L1 protein levels. Moreover, we analysed PD-L1 expression on an in vivo IH model with old and young mice. In subjects up to 55 years of age, severe OSA increased PD-L1 surface protein and mRNA level expression on monocytes and soluble-PD-L1 protein concentration in plasma compared to HV. PD-L1 and hypoxia-induced factor (HIF)-1α expression correlated with age in HV, whereas in patients with OSA there was a negative relationship. In the mice exposed to IH, PD-L1 expression on F4/80+ splenocytes was also only increased in young animals. HIF-1α expression was significantly higher in patients with OSA than in HV in subjects up to 55 years of age, while PD-L1 expression in monocytes was related to HIF-1α expression in young patients with OSA. PD-L1 upregulation in patients with OSA as a consequence of HIF-1α activation occurs mainly in young patients. In older patients with OSA, upregulation was not detected, possibly due to impaired oxygen sensitivity.

Sections du résumé

BACKGROUND AND OBJECTIVE
In obstructive sleep apnoea (OSA), intermittent hypoxia (IH) compromises immune surveillance through the upregulation of the programmed cell death-1 (PD-1) receptor and its ligand (PD-L1). Because the risk of OSA-related cancer depends on age, we assessed PD-L1/PD-1 expression in middle-aged and older patients with OSA as well as in a murine model.
METHODS
PD-L1 expression was studied in 41 patients with severe OSA and 40 healthy volunteers (HV), divided into two groups (≤55 and >55 years of age). We used flow cytometry, quantitative PCR (qPCR) and ELISA to determine PD-L1 expression on monocytes and plasma PD-L1 protein levels. Moreover, we analysed PD-L1 expression on an in vivo IH model with old and young mice.
RESULTS
In subjects up to 55 years of age, severe OSA increased PD-L1 surface protein and mRNA level expression on monocytes and soluble-PD-L1 protein concentration in plasma compared to HV. PD-L1 and hypoxia-induced factor (HIF)-1α expression correlated with age in HV, whereas in patients with OSA there was a negative relationship. In the mice exposed to IH, PD-L1 expression on F4/80+ splenocytes was also only increased in young animals. HIF-1α expression was significantly higher in patients with OSA than in HV in subjects up to 55 years of age, while PD-L1 expression in monocytes was related to HIF-1α expression in young patients with OSA.
CONCLUSION
PD-L1 upregulation in patients with OSA as a consequence of HIF-1α activation occurs mainly in young patients. In older patients with OSA, upregulation was not detected, possibly due to impaired oxygen sensitivity.

Identifiants

pubmed: 30656807
doi: 10.1111/resp.13470
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
Cd274 protein, mouse 0
HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

684-692

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Asian Pacific Society of Respirology.

Auteurs

Carolina Cubillos-Zapata (C)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Cristina Balbás-García (C)

Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Jose Avendaño-Ortiz (J)

The Innate Immune Response Group, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Victor Toledano (V)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
The Innate Immune Response Group, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Marta Torres (M)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
Sleep Laboratory, Pneumology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Isaac Almendros (I)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
Biophysics and Bioengineering Unit, Faculty of Medicine, University of Barcelona-IDIBAPS, Barcelona, Spain.

Raquel Casitas (R)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Ester Zamarrón (E)

Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Aldara García-Sánchez (A)

Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Jaime Feliu (J)

Oncology Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.
Biomedical Research Networking Center on Cancer (CIBERONC), Madrid, Spain.

Luis A Aguirre (LA)

The Innate Immune Response Group, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Ramón Farre (R)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
Biophysics and Bioengineering Unit, Faculty of Medicine, University of Barcelona-IDIBAPS, Barcelona, Spain.

Eduardo López-Collazo (E)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
The Innate Immune Response Group, La Paz University Hospital, IdiPAZ, Madrid, Spain.

Francisco García-Rio (F)

Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain.
Respiratory Diseases Group, Respiratory Service, La Paz University Hospital, IdiPAZ, Madrid, Spain.
Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH